

UC Berkeley

UC Berkeley Previously Published Works

Title

Associations Between Systemic Omega-3 Fatty Acid Levels With Moderate-to-Severe Dry Eye Disease Signs and Symptoms at Baseline in the Dry Eye Assessment and Management Study.

Permalink

<https://escholarship.org/uc/item/4wp7q1t0>

Journal

Eye & Contact Lens Science & Clinical Practice, 47(1)

ISSN

1542-2321

Authors

Kuklinski, Eric J
Hom, Milton M
Ying, Gui-Shuang
[et al.](#)

Publication Date

2021

DOI

10.1097/icl.0000000000000687

Peer reviewed

Associations Between Systemic Omega-3 Fatty Acid Levels With Moderate-to-Severe Dry Eye Disease Signs and Symptoms at Baseline in the Dry Eye Assessment and Management Study

Eric J. Kuklinski, BA, Milton M. Hom, O.D., F.A.A.O., Gui-Shuang Ying, Ph.D., Meng C. Lin, O.D., Ph.D., Robert S. Chapkin, Ph.D., Richard Jones, Ph.D., Ann Moser, B.A., Ka Yeun Kim, BS, Maureen G. Maguire, Ph.D., and Penny A. Asbell, M.D., M.B.A., F.A.C.S., the DREAM Study Research Group

Purpose: Omega-3 (n-3) fatty acid supplementation is used to treat systemic inflammatory diseases, but the role of n-3 in the pathophysiology and therapy of dry eye disease (DED) is not definitive. We evaluated the

From the Ophthalmology (E.J.K., K.Y.K., P.A.A.), Icahn School of Medicine at Mount Sinai, New York, NY; Private Practice (M.M.H.), Azusa, CA; Ophthalmology (G.-S.Y., M.G.M.), University of Pennsylvania, Philadelphia, PA; Clinical Research Center (M.C.L.), University of California, Berkeley, CA; Program in Integrative Nutrition & Complex Diseases (R.S.C.), Texas A&M University, College Station, TX; Kennedy Krieger Institute (R.J., A.M.), Baltimore, MD; and Ophthalmology (P.A.A.), University of Tennessee, Memphis, TN

P. A. Asbell reports personal fees from Santen, personal fees from Shire, grants and personal fees from Novartis, personal fees from Medscape, grants and personal fees from MC2 Therapeutics, grants, personal fees, and nonfinancial support from Valeant, Bausch& Lomb, personal fees from Allergan, personal fees from ScientiaCME, grants and personal fees from Rtech, personal fees from Oculus, grants and personal fees from Miotech, personal fees and nonfinancial support from Shire, personal fees and nonfinancial support from Santen, personal fees and nonfinancial support from CLAO, and personal fees from Vindico, outside the submitted work. M. C. Lin reports grants from Amorphex Therapeutics, grants from Cooper-Vision, Inc, grants from Essilor USA, grants from GLIA LLC, grants from Johnson & Johnson, grants from Leo Lens, Inc, grants from Orinda Pharma, grants from Verily Life Science, grants from Viewpoint Pharmaceuticals, personal fees from Google X, personal fees from Health Advances, personal fees from Novartis, and personal fees from Shire, during the conduct of the study. M. M. Hom reports grants from Allergan, Takeda, Tarsus Pharmaceuticals, Bausch Health, Hovine Scientia, Tear Solutions, and Kala Pharmaceuticals. E. J. Kuklinski reports a grant from MC2 Therapeutics. M. J. Maguire reports personal fees from Genentech/Roche. The remaining authors have no conflicts of interest to disclose.

Supported by cooperative agreements U10EY022879 and U10EY022881 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services. Additional support provided from the Office of Dietary Supplements National Institutes of Health, Department of Health and Human Services.

Presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 2, 2018 Honolulu, HI.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.eyeandcontactlensjournal.com).

The members of the DREAM Study Research Group are listed in the Supplemental Digital Content, Appendix, <http://links.lww.com/ICL/A131>.

Address correspondence to Maureen G. Maguire, Ph.D., University of Pennsylvania, 3711 Market Street, Suite 801, Philadelphia, PA 19104; e-mail: maguirem@pennmedicine.upenn.edu

Accepted November 24, 2019.

DOI: 10.1097/ICL.0000000000000687

relationship of systemic n-3 levels with signs and symptoms at baseline in the Dry Eye Assessment and Management (DREAM) Study.

Methods: Blood samples from participants at baseline were analyzed for n-3 and n-6, measured as relative percentage by weight among all fatty acids in erythrocytes. Symptoms were evaluated using the Ocular Surface Disease Index. Signs including conjunctival staining, corneal staining, tear breakup time (TBUT), and Schirmer's test with anesthesia were also evaluated.

Results: There was no correlation between the systemic n-3 levels and DED symptoms. When the associations with signs of DED were assessed, lower DHA levels were associated with higher conjunctival staining, with mean scores of 3.31, 2.96, and 2.82 for low, medium, and high levels of DHA, respectively (linear trend $P=0.007$). None of the other signs were associated with DHA or the other measures of n-3.

Conclusion: Previous studies have found varying results on the role of n-3 supplementation with the signs and symptoms of DED. Among patients with DED enrolled in the DREAM Study, lower systemic n-3 levels were not associated with worse symptoms and most signs of DED.

Key Words: Dry eye disease—Omega-3 fatty acids—Inflammation.

(*Eye & Contact Lens* 2021;47: 2–7)

Dry eye disease (DED) is a chronic, inflammatory ocular condition affecting approximately 14% of adults in the United States.^{1–3} Typical treatment of DED includes artificial tears or eye drops such as cyclosporine (Restasis) and lifitegrast (Xiidra) that affect inflammatory mediators in the eye.^{4,5} However, these therapies do not work for everyone. Therefore, clinicians and their DED patients continue to seek better methods to treat the signs and symptoms of DED and are often attracted to “natural” treatments such as nutritional supplements.

Omega-3 (n-3) polyunsaturated fatty acid (PUFA) supplementation is often recommended for prevention and treatment of a variety of diseases ranging from coronary heart disease to DED, in large part because of the anti-inflammatory properties of n-3.^{6–13} High levels of two n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in fish and other seafood.

n-3 PUFAs exhibit anti-inflammatory properties, in part, because they compete with arachidonic acid (AA) as a substrate for cyclooxygenases and 5-lipoxygenase. PUFAs derived from n-3 and n-6 compete for enzymes involved in their metabolism. From a metabolic perspective, n-3 fatty acids suppress the interconversion

of n-6 essential fatty acids (EFAs) to AA. There is an overproduction of pro-inflammatory prostaglandin E2 (PGE2) and underproduction of anti-inflammatory PGE1 and PGE3 when the systemic levels of n-6/n-3 fatty acid ratio are high.⁷ In addition to anti-inflammatory properties, n-3 fatty acids may also provide neuroprotective and neuroregenerative effects.^{14,15}

The systemic ratio of n-6/n-3 has been widely discussed as an objective measure of maintaining ideal fatty acid balance to maximize anti-inflammatory effects of n-3. The ideal n-6/n-3 ratio in the diet is about 2/1,¹⁶ as is seen in the Mediterranean diet, rich in cold-water fish and natural oils. An unfortunate consequence of industrialization of food production may be a disturbance in the ratio of n-6/n-3 fatty acids, with a higher consumption of n-6 relative to n-3. From a teleologic perspective, humans have evolved with a diet that consisted of a 1/1 ratio of n-6/n-3 fatty acids, to current Western diets, with ratios closer to 15/1.¹⁷ Studies suggest that increasing systemic levels of n-3 fatty acids, like EPA and DHA, by oral supplementation would help in the lowering of the n-6/n-3 ratio and hence have an anti-inflammatory effect.^{7,8,17–19} When the n-6/n-3 ratio is 4/1 or lower, there is competitive inhibition of the conversion of di-homo-linolenic acid (DGLA) to AA, resulting in more anti-inflammatory PGE1.^{18,20} Therefore, it has been recommended that people ingest more n-3 than n-6 to help keep that ratio low to enhance the anti-inflammatory effects.^{8,21,22}

Some studies have shown anti-inflammatory effects of n-3 intake as measured by decreased T-cell infiltration, decreased systemic and tear inflammatory cytokines, and inhibition of ocular surface human leukocyte antigen D-related (HLA-DR), a biomarker believed to be associated with DED.^{19,23–29}

Previous randomized clinical trials have shown varying results of n-3's effectiveness in decreasing the signs and symptoms of DED and have used a wide variety of doses of both n-3 and n-6.^{9,27,30–32} Three of the trials measured blood levels of fatty acids in study participants at baseline and follow-up.^{9,29,32} In a highly selective study population of patients having high tear osmolarity and relatively mild symptoms, Epitropoulos et al. found that 3 months of n-3 supplementation (2,240 mg daily) increased the n-3 index in plasma, decreased tear osmolarity, improved tear stability, and reduced symptoms over a 3-month period. However, the association between plasma n-3 levels and signs and symptoms was not evaluated.⁹

Macasai et al. found a significant increase of the n-3 and decrease of the n-6/n-3 ratio in both red blood cells (RBCs) and plasma of the n-3 experimental group after 1 year of treating subjects with 3,300 mg of n-3 daily. Improvement in signs and symptoms were variable across both the experimental and placebo group. However, no direct comparison was made between the systemic levels of n-3 and the signs and symptoms of DED.³²

The Dry Eye Assessment and Management (DREAM) Study was a large-scale, real-world, multicenter, double-masked, placebo-controlled randomized clinical trial measuring the effects of n-3 supplementation on DED.³³ Recently reported results from the DREAM Study showed that after 1 year of supplementation, there was no difference between n-3 (3000 mg of n-3 daily) and placebo (5000 mg of refined olive oil daily) on both signs and symptoms of DED.³⁰ In this report, we evaluated the association between systemic n-3 levels at baseline with the severity of signs and symptoms in DREAM participants, both in patients taking low-dose n-3 supplements and those not taking n-3 supplements.

METHODS

Overview

The DREAM Study was multicenter, double-masked, placebo-controlled randomized clinical trial measuring the effects of n-3 supplementation on DED (ClinicalTrials.gov number NCT02128763). To enhance the generalizability of the study findings, the DREAM Study used minimally restrictive inclusion and exclusion criteria to capture a broad spectrum of typical DED patients seeking additional treatment for their symptoms. The study enrolled subjects with moderate-to-severe DED symptoms, as defined by the Ocular Surface Disease Index (OSDI; Allergan), and who also demonstrated repeatable signs of DED.³³ Eligible patients needed a score on the OSDI between 25 and 80, inclusive, at a screening visit and between 21 and 80, inclusive, at an eligibility confirmation visit. Scores on the OSDI range from 0 to 100, where 0 indicates no ocular discomfort. Patients needed to have at least 1 eye with at least 2 of the following 4 signs: conjunctival lissamine green staining score ≥ 1 on a scale of 0 to 6; corneal fluorescein staining score ≥ 4 on a scale of 0 to 15; tear film break up time (TBUT) ≤ 7 sec; and Schirmer test with anesthesia measurement ≥ 1 to ≤ 7 mm/5 min. The same qualifying signs had to be present in the same eye on examination at both the screening and eligibility confirmation visits. Fluorescein corneal staining was scored using the National Eye Institute [NEI]/industry-recommended scoring guidelines.³⁴ Lissamine green conjunctival staining was scored using a modified version of the NEI/industry-recommended scoring guidelines—the entire temporal and the entire nasal section of each eye were graded on a scale of 0 to 3 (0: no staining, 3: severe staining) for a total possible score of 6 in each eye. Subjects reported usage and dosage of dietary supplements containing n-3. Subjects taking greater than 1,200 mg n-3 daily were excluded. In addition, blood was collected at baseline to assess systemic fatty acids levels based on lipid analysis of erythrocytes. Blood samples were shipped to the Peroxisomal Diseases Laboratory at the Kennedy Krieger Institute in Baltimore, MD within 24 hr of collection for lipid analysis.³³

Subjects were enrolled from 27 sites across the United States, which included private and academic ophthalmology and optometry practices. The DREAM Study was approved by the respective clinical center institutional review boards or a centralized institutional review board (University of Pennsylvania). The DREAM Study was in compliance with the Health Insurance Portability and Accountability Act and adhered to the principles of the Declaration of Helsinki.

Blood Analysis

Red blood cell total lipid fatty acid profiles were assessed at The Kennedy Krieger Institute (Baltimore, MD). Venous blood (~8 mL) was drawn into EDTA tubes and shipped overnight at room temperature for processing and analysis. Red blood cells were separated from plasma by centrifugation and the plasma and buffy coat removed. The RBCs were resuspended in 4°C phosphate buffered saline (PBS; Sigma Aldrich), centrifuged, and the PBS and any remaining buffy coat removed. This washing procedure was then repeated. The packed RBCs were stored under nitrogen at -80°C while awaiting analysis. Red blood cell membrane total lipid fatty acids were derivatized to their pentafluoro-benzyl bromide fatty acid esters, which were separated and identified by negative ion gas

chromatography mass spectrometry using a 50-meter SP2560 column (Supelco), as previously described.^{35,36} Each run was required to pass clinical laboratory quality control before the data were released. Red blood cell fatty acids are presented as percent of total lipids.

Statistical Analysis

Associations between measures of n-3 (EPA, DHA, n-3 index (EPA+DHA), and ratio of n-6/n-3) and dry eye symptoms (OSDI) and signs (conjunctival staining, corneal staining, TBUT, and Schirmer's test) were evaluated at baseline. EPA and DHA levels were grouped into categories that placed approximately 50% of patients into the medium category and 25% into the low and high categories. The scores of dry eye symptoms and signs were compared among levels of EPA and DHA and tertiles of both EPA+DHA and ratio of n-6/n-3 using analysis of variance with tests of linear trend. Linear regression analyses were performed with n-3 measures as continuous independent variables for predicting dry eye symptoms or signs, adjusted for age, sex, and presence of Sjogren syndrome. For the regression analyses of associations between n-3 measures and dry eye signs, the generalized estimating equations approach was used to accommodate the inter-eye correlation in signs from both eyes of a participant. All statistical analyses were performed in SAS v9.4 (SAS Institute Inc, Cary, NC). After applying a Bonferroni adjustment to accommodate the multiple comparisons of n-3 levels across the 4 signs of DED, only *P* values less than 0.0125 were considered statistically significant when analyzing signs.

RESULTS

Systemic levels of fatty acids of all DREAM participants at baseline are listed in Table 1. Subjects who were taking some form of n-3 supplementation before entering the study reported a median daily dose of 600 mg with an interquartile range of 330 to 900 mg. These subjects had significantly higher levels of EPA, DHA, and n-3 index ($P < 0.0001$) and a significantly lower n-6/n-3 ratio ($P < 0.0001$) than subjects not taking any n-3 supplementation before entering the study. There were no significant differences in signs or symptoms of DED between these groups after adjusting for age, sex, and presence of Sjogren Syndrome (Table 2).

There were no significant associations between n-3 measures and dry eye symptoms assessed using OSDI (all *P*-values ≥ 0.15 , Table 3). The association between n-3 measures and dry eye signs is reported in Table 4. After accounting for multiple comparisons, lower DHA levels were associated with higher conjunctival staining, with mean scores of 3.31, 2.96, and 2.82 for low, medium, and high levels of DHA, respectively (linear trend $P = 0.007$).

The analysis of the association of n-3 measures and dry eye symptoms and signs using data excluding participants taking n-3 supplements at baseline showed results similar to those cited previously for the OSDI symptom scores and most of the DED signs (see Table 1, Supplemental Digital Contents 1 and 2, <http://links.lww.com/ICL/A129> and 2, <http://links.lww.com/ICL/A130>). However, the inverse association of the EPA level with tear break-up time (lower EPA values associated with longer [better tear break up times]) that was of borderline statistical significance in Table 4 ($P = 0.014$) was statistically significant when participants taking n-3 supplements were excluded ($P = 0.004$). Results were similar when the concentration of the fatty acids, rather than the percent of total lipids, was used in analyses.

DISCUSSION

The DREAM cohort at baseline is a representative sample of the United States population in terms of systemic fatty acid concentrations. A study by Harris et al.³⁷ defined systemic fatty acid norms of the US population by measuring the systemic fatty acid levels in erythrocytes of nearly 160,000 people. The mean baseline n-3 index (EPA+DHA) of the DREAM Study population at baseline approximately corresponds to the 50th percentile found by Harris et al.³⁷

Lipid analysis of erythrocytes provides the most accurate and objective measure of the systemic levels of n-3. Erythrocytes are not influenced by what has been recently ingested because their lifespan is approximately 4 months and therefore will reflect a person's overall diet of the past 4 months.³⁸ This gives an accurate measure of how n-3 supplementation changes n-3 levels throughout the body and may give an indication of how n-3 levels correlate with signs and symptoms of disease. Measurements of fatty acids on erythrocytes are commonly performed in n-3 supplementation studies to provide objective evidence of compliance

TABLE 1. Baseline Systemic Levels of n-3 Measures in DREAM Participants by Use of n-3 Supplements at Baseline

Baseline Fatty Acid Measure	Participants		Taking n-3 Supplements		<i>P</i> ^a
	All (N=520)	No (N=386)	Yes (N=134)		
Eicosapentaenoic acid (EPA), percent of total lipids by weight					
Mean (SD)	0.60 (0.40)	0.48 (0.24)	0.96 (0.54)		<0.0001
Median (first quartile, third quartile)	0.47 (0.35, 0.70)	0.41 (0.32, 0.56)	0.81 (0.58, 1.18)		
Docosahexaenoic acid (DHA), percent of total lipids by weight					
Mean (SD)	3.89 (1.15)	3.62 (1.03)	4.65 (1.13)		<0.0001
Median (first quartile, third quartile)	3.75 (3.04, 4.61)	3.48 (2.84, 4.22)	4.62 (3.80, 5.38)		
n-3 index (EPA+DHA), percent of total lipids by weight					
Mean (SD)	4.49 (1.46)	4.10 (1.21)	5.61 (1.55)		<0.0001
Median (first quartile, third quartile)	4.24 (3.43, 5.29)	3.88 (3.23, 4.72)	5.45 (4.35, 6.57)		
Ratio of n-6:n-3					
Mean (SD)	4.77 (1.38)	5.15 (1.24)	3.69 (1.15)		<0.0001
Median (first quartile, third quartile)	4.75 (3.81, 5.74)	5.18 (4.29, 5.95)	3.55 (2.89, 4.22)		

^aFrom two-sample *t* test for comparison of means.

DREAM, Dry Eye Assessment and Management.

TABLE 2. Baseline Dry Eye Symptoms and Signs by Use of n-3 Supplements at Baseline

Dry Eye Symptoms and Signs at Baseline	Minimum, Maximum ^a	Taking n-3 Supplements		p ^b
		No (N=386), Mean (SE)	Yes (N=134), Mean (SE)	
OSDI score	21, 81	42.4 (1.33)	43.0 (1.68)	0.71
Conjunctival staining score	0, 6	2.94 (0.07)	2.91 (0.12)	0.84
Corneal staining score	0, 15	3.81 (0.14)	3.88 (0.23)	0.81
TBUT (seconds)	0, 19	3.12 (0.08)	3.08 (0.14)	0.78
Schirmer test (mm)	0, 36	9.67 (0.33)	9.30 (0.55)	0.55

^aMinimum and maximum scores among 520 DREAM patients.

^bFrom analysis of variance for comparison of dry eye symptoms (OSDI) measured at the person level and from using the generalized estimating equations approach for comparison of dry eye signs measured at the eye level, adjusted by age, sex, and presence of Sjogren syndrome.

DREAM, Dry Eye Assessment and Management; OSDI, Ocular Surface Disease Index.

with treatment, measure the change of systemic levels in the active group of a RCT, and analyze if the change in systemic levels correlate with changes in signs and symptoms.^{9,29,33,37,39}

The eligibility criteria of the DREAM Study allowed people who were taking low doses of n-3 supplements (≤1,200 mg) to still enroll in the study.³³ Erythrocyte analysis showed that the subjects who were taking n-3 supplementation before entering the study (n=134) actually had significantly higher systemic levels of n-3 as compared with those subjects who were not taking any n-3 supplementation before entering the study (n=386) (Table 1). However, despite these significant differences in systemic levels of n-3 between the two groups, there were no statistically significant difference in severity of DED signs and symptoms (Table 2). This finding helps support the conclusion that systemic levels of n-3 are not associated with the severity of DED.

Signs and symptoms of DED were compared with several different metrics for determining systemic levels of n-3 (EPA, DHA, n-3 index [EPA+DHA], and n-6/n-3) because these metrics have been extensively studied and are believed to be behind the mechanism of n-3's anti-inflammatory effects.^{7,8,17–22,37} Despite analyzing systemic levels⁷ several different ways, no correlation was found between

systemic levels and symptoms of DED. In addition, the majority of DED signs did not correlate with systemic levels of n-3.

There was an association of systemic levels of EPA and TBUT that was of borderline statistical significance after adjusting for multiple comparisons and statistically significant among patients not taking n-3 supplements (Table 4 and see Table 1, Supplemental Digital Content 1, <http://links.lww.com/ICL/A129>). A lower systemic level of EPA was associated with a longer TBUT. However, the estimated decrease in TBUT with each increase of 1% of EPA was approximately 0.5 sec, an amount with little clinical significance. Nonetheless, the effect is the opposite direction of what one would expect. It has been demonstrated that DHA and EPA are detectable and are in higher levels in the human tear film resulting from taking omega-3 supplementation, suggesting that oral intake of omega-3 supplements has sufficient bioavailability.⁴⁰ It has also been suggested that elevated levels of PUFA from consumption of EFA-containing supplements may lead to more disordered and less tightly packed tear-lipid films, with reduced water evaporation resistance, and as a result, TBUT becomes shorter.^{41,42} Our results support this notion that a higher serum n-3 level was associated with shorter TBUT.

TABLE 3. Adjusted Mean Values of the Ocular Surface Disease Index (OSDI) by n-3 Measures at Baseline

Baseline n-3 Measure	Participants (N=520)	Baseline OSDI		p ^a
		Mean	(SE)	
EPA, percent of total lipids by weight				0.39
Low (≤0.36)	136	42.5	(1.7)	
Medium	255	43.9	(1.4)	
High (>0.70)	129	40.8	(1.7)	
As continuous slope (SE)			-0.69 (1.82)	0.71
DHA, percent of total lipids by weight				0.13
Low (≤3.0)	127	42.9	(1.7)	
Medium	263	44.0	(1.4)	
High (>4.6)	130	40.0	(1.6)	
As continuous slope (SE)			-0.89 (0.61)	0.15
n-3 index (EPA+DHA), percent of total lipids by weight				0.31
1st tertile (≤3.7)	175	43.2	(1.6)	
2nd tertile (>3.7, ≤4.9)	173	43.2	(1.5)	
3rd tertile (>4.9)	172	41.5	(1.5)	
As continuous slope (SE)			-0.60 (0.49)	0.21
Ratio of n-6:n-3				0.27
1st tertile (≤4.1)	172	41.0	(1.5)	
2nd tertile (>4.1, ≤5.4)	173	43.9	(1.6)	
3rd tertile (>5.4)	175	42.9	(1.6)	
As continuous slope (SE)			0.63 (0.49)	0.19

^aP-value from test of linear trend, adjusted by age, sex, and the presence of Sjogren syndrome.

TABLE 4. Adjusted Mean Values of Measurements of Dry Eye Signs by n-3 Measures at Baseline

Baseline n-3 Measure	Eyes (N=1,040)	Conjunctival Staining Score		Corneal Staining Score		TBUT (seconds)		Schirmer Test (mm)	
		Mean (SE)	P ^a	Mean (SE)	P ^a	Mean (SE)	P ^a	Mean (SE)	P ^a
EPA, percent of total lipids by weight			0.11		0.34		0.03		0.52
Low (≤0.36)	272	3.23 (0.16)		3.89 (0.31)		3.35 (0.17)		10.2 (0.69)	
Medium	510	2.89 (0.13)		4.14 (0.26)		3.03 (0.14)		9.73 (0.61)	
High (>0.70)	258	2.96 (0.15)		4.20 (0.28)		2.92 (0.17)		9.63 (0.78)	
As continuous slope (SE)		-0.04 (0.15)	0.81	0.001 (0.26)	0.99	-0.37 (0.15)	0.014	-0.33 (0.76)	0.66
DHA, percent of total lipids by weight			0.007		0.81		0.22		0.71
Low (≤3.0)	254	3.31 (0.16)		3.94 (0.32)		3.36 (0.17)		9.78 (0.73)	
Medium	526	2.96 (0.12)		4.32 (0.26)		2.96 (0.14)		9.66 (0.58)	
High (>4.6)	260	2.82 (0.16)		3.85 (0.29)		3.07 (0.18)		10.1 (0.79)	
As continuous slope (SE)		-0.13 (0.05)	0.02	-0.03 (0.10)	0.75	-0.06 (0.07)	0.45	0.03 (0.26)	0.91
n-3 index (EPA+DHA) percent of total lipids by weight			0.02		0.54		0.38		0.95
1st tertile (≤3.7)	350	3.25 (0.14)		4.14 (0.29)		3.22 (0.15)		9.84 (0.64)	
2nd tertile (>3.7, ≤4.9)	346	2.86 (0.14)		4.20 (0.27)		2.96 (0.15)		9.71 (0.66)	
3rd tertile (>4.9)	344	2.88 (0.14)		3.94 (0.28)		3.06 (0.17)		9.89 (0.72)	
As continuous slope (SE)		-0.08 (0.04)	0.04	-0.02 (0.08)	0.80	-0.06 (0.05)	0.25	-0.01 (0.21)	0.97
Ratio of n-6:n-3			0.03		0.68		0.21		0.70
1st tertile (≤4.1)	344	2.89 (0.14)		3.99 (0.28)		3.00 (0.17)		10.5 (0.74)	
2nd tertile (>4.1, ≤5.4)	346	2.89 (0.13)		4.18 (0.28)		3.00 (0.15)		9.66 (0.65)	
3rd tertile (>5.4)	350	3.23 (0.14)		4.11 (0.29)		3.26 (0.16)		9.76 (0.64)	
As continuous slope (SE)		0.11 (0.05)	0.02	-0.02 (0.09)	0.79	0.10 (0.06)	0.10	0.01 (0.23)	0.99

^aFrom test of linear trend using the generalized estimating equations approach to account for with inter-eye correlation, adjusted by age, sex, and the presence of Sjogren syndrome.

The results from this study bring into question the role of n-3 in DED. All results, whether statistically significant or not, are likely not clinically significant because the mean difference in clinical signs between the high and low systemic levels is approximately 0.5 sec (TBUT), less than one point (corneal [out of 15] and conjunctival staining [out of six maximum]) or less than 1.5 mm (Schirmer's test). These results bring into question the assertion that n-3 fatty acids are beneficial for the treatment of DED and the mechanism by which they affect DED.

The conclusions of this study are limited due to the enrollment criteria of the DREAM clinical trial.³⁰ Only patients suffering from DED were evaluated, so it cannot be determined whether a population of non-DED patients would have had higher systemic levels of n-3. However, enrolled subjects ranged from moderate-to-severe DED, and the mean systemic n-3 levels of these subjects were approximately equal to the 50th percentile of the population in an observational study by Harris et al.³⁷ Therefore, it is likely that the n-3 levels found in this population of DED patients would be similar to a population of non-DED patients. Another limitation is due to subjects being permitted to take n-3 supplements (≤1,200 mg) before entering the study. It cannot be inferred if these supplements were beneficial in treating their signs or symptoms of DED. However, it is still true that they are suffering from moderate-to-severe DED and that despite having higher systemic levels of n-3 (Table 1), they still had similar severity of signs and symptoms of those not taking supplements (see Table 2, Supplemental Digital Content 2, <http://links.lww.com/ICL/A130>). In addition, this study did not quantify n-3 bioavailability in the tear film.

There is still variable evidence that n-3 supplementation is beneficial with respect to other diseases such as cardiac disease. The REDUCE-IT study found that 2,000 mg of ethyl eicosapentaenoic acid daily significantly lowered the risk of ischemic events, including cardiovascular death in patients with elevated triglyceride levels.⁴³ However, a recent meta-analysis of 10 studies involving 77,917 individuals on n-3 for treating cardiovascular disease

concluded that “n-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events.”⁴⁴

The cross-sectional associations provided in this report demonstrated that there was no association between systemic levels of n-3 and the severity of DED in patients in their normal lives before entering an interventional randomized clinical trial. This supports the conclusion that n-3 may not play a significant role in the cause or therapy of DED. More evidence is needed to determine whether and how n-3 may affect the pathophysiology of DED.

REFERENCES

- Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. *Eye Contact Lens* 2014;40:248–256.
- Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. *Ocul Surf* 2017;15:438–510.
- Farrand KF, Fridman M, Stillman IO, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 Years and older. *Am J Ophthalmol* 2017;182:90–98.
- RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% [package insert]. Irvine, CA, Allergan, Inc., 2012.
- XIIDRA™ (lifitegrast Ophthalmic solution) 5% [package insert]. Lexington, MA, Shire US Inc., 2016.
- Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim Biophys Acta* 2015;1851:469–484.
- Calder PC. N-3 polyunsaturated fatty acids and inflammation: From molecular biology to the clinic. *Lipids* 2003;38:343–352.
- Simopoulos AP. Omega-6/omega-3 essential fatty acids: Biological effects. *World Rev Nutr Diet* 2009;99:1–16.
- Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. *Cornea* 2016;35:1185–1191.
- Roy S, Brasky TM, Belury MA, et al. Associations of erythrocyte omega-3 fatty acids with biomarkers of omega-3 fatty acids and inflammation in breast tissue. *Int J Cancer* 2015;137:2934–2946.
- Shen J, Hafeez A, Stevenson J, et al. Omega-3 fatty acid supplement prevents development of intracranial atherosclerosis. *Neuroscience* 2016;334:226–235.

12. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol* 2011;58:2047–2067.
13. Dijk MV, Vitek JR. *Fish Oil: Production, Consumption, and Health Benefits*. Hauppauge, NY, Nova Biomedical, Nova Biomedical Books, 2012.
14. Chinnery HR, Golborne CN, Downie LE. Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: A pilot study. *Ophthalmic Physiol Opt* 2017;37:473–481.
15. Dyall SC. Long-chain omega-3 fatty acids and the brain: A review of the independent and shared effects of EPA, DPA, and DHA. *Front Aging Neurosci* 2015;7:1–15.
16. Simopoulos AP, Leaf A, Salem N Jr. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. *J Am Coll Nutr* 1999;18:487–489.
17. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed Pharmacother* 2002;56:365–379.
18. Miljanovic B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. *Am J Clin Nutr* 2005;82:887–893.
19. Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. *Curr Opin Clin Nutr Metab Care* 2001;4:115–121.
20. Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr* 1998;128:1411–1414.
21. Zanoaga O, Jurj A, Raduly L, et al. Implications of dietary omega-3 and omega-6 polyunsaturated fatty acids in breast cancer. *Exp Ther Med* 2018;15:1167–1176.
22. Torres-Castillo N, Silva-Gomez JA, Campos-Perez W, et al. High dietary omega-6:omega-3 PUFA ratio is positively associated with excessive adiposity and waist circumference. *Obes Facts* 2018;11:344–353.
23. Fontes JD, Rahman F, Lacey S, et al. Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study in a community-based cohort. *Atherosclerosis* 2015;240:431–436.
24. Epstein SP, Gadaria-Rathod N, Wei Y, et al. HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease. *Exp Eye Res* 2013;111:95–104.
25. Wei Y, Gadaria-Rathod N, Epstein S, et al. Tear cytokine profile as a non-invasive biomarker of inflammation for ocular surface diseases: Standard operating procedures. *Invest Ophthalmol Vis Sci* 2013;54:8327–8336.
26. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. *Cornea* 2009;28:1023–1027.
27. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. *Acta Ophthalmol* 2011;89:e591–597.
28. Roy NS, Wei Y, Kuklinski E, et al. The growing need for validated biomarkers and endpoints for dry eye clinical Research. *Invest Ophthalmol Vis Sci* 2017;58: BIO1–BIO19.
29. Deinema LA, Vingrys AJ, Wong CI, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. *Ophthalmology* 2017;124:43–52.
30. The Dry Eye Assessment and Management Study Research Group. n-3 fatty acid supplementation for treatment of dry eye disease. *N Engl J Med* 2018;378:1681–1690.
31. Bhargava R, Kumar P, Kumar M, et al. A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. *Int J Ophthalmol* 2013;6: 811–816.
32. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Trans Am Ophthalmol Soc* 2008;106:336–356.
33. Asbell PA, Maguire MG, Peskin E, et al. Dry eye assessment and management (DREAM©) study: Study design and baseline characteristics. *Contemp Clin Trials* 2018;71:70–79.
34. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. *CLAO J* 1995;21:221–232.
35. Lagerstedt SA, Hinrichs DR, Batt SM, et al. Quantitative determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. *Mol Genet Metab* 2001;73:38–45.
36. Steinberg S, Jones R, Tiffany C, et al. Investigational methods for peroxisomal disorders. *Curr Protoc Hum Genet* 2008;Chapter 17: Unit 17: 16.
37. Harris WS, Pottala JV, Varvel SA, et al. Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: Observations from 160,000 patients. *Prostaglandins Leukot Essent Fatty Acids* 2013;88:257–263.
38. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res* 2008;47:348–380.
39. Gan RW, Demoruelle MK, Deane KD, et al. Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. *Ann Rheum Dis* 2017;76: 147–152.
40. Walter SD, Gronert K, McClellan AL, et al. omega-3 tear film lipids correlate with clinical measures of dry eye. *Invest Ophthalmol Vis Sci* 2016;57: 2472–2478.
41. Borchman D, Foulks GN, Yappert MC, et al. Changes in human meibum lipid composition with age using nuclear magnetic resonance spectroscopy. *Invest Ophthalmol Vis Sci* 2012;53:475–482.
42. Shrestha RK, Borchman D, Foulks GN, et al. Analysis of the composition of lipid in human meibum from normal infants, children, adolescents, adults, and adults with meibomian gland dysfunction using (1)H-NMR spectroscopy. *Invest Ophthalmol Vis Sci* 2011;52:7350–7358.
43. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;380:11–22.
44. Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77917 individuals. *JAMA Cardiol* 2018;3:225–234.